股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年11月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 東曜藥業股份有限公司 | | | 呈交日期: | 2025年12月4日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01875 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | | 已發行股份總數 | | | 上月底結存 | | | 772,787,887 | | | 0 | | 772,787,887 | | 增加 / 減少 ( ...

Core Insights - Dongyao Pharmaceutical reported a revenue of 622 million yuan for the nine months ending September 30, 2025, representing a 23% decrease compared to the same period last year, primarily due to intensified market competition for self-developed products [1] - The company experienced a net loss of 3.37 million yuan during this period, contrasting with a net profit of 35.4 million yuan in the same period last year [1] - As of September 30, 2025, the company's current assets totaled 656 million yuan, non-current assets were 721 million yuan, current liabilities amounted to 266 million yuan, non-current liabilities were 385 million yuan, and total net assets slightly decreased to 726 million yuan from 730 million yuan as of December 31, 2024 [1] Financial Performance - Revenue for the nine-month period was 622 million yuan, down 23% year-on-year [1] - Net loss recorded was 3.37 million yuan, compared to a net profit of 35.4 million yuan in the previous year [1] - Total net assets decreased slightly to 726 million yuan from 730 million yuan [1] Balance Sheet Overview - Current assets stood at 656 million yuan [1] - Non-current assets were reported at 721 million yuan [1] - Current liabilities were 266 million yuan, while non-current liabilities were 385 million yuan [1]

Group 1 - The Hong Kong stock market opened slightly higher today, with the Hang Seng Index at 26,754.93 points, up 58.52 points, or 0.22% [1] - The Hang Seng Technology Index rose to 5,939.69 points, increasing by 15.30 points, or 0.26% [3] Group 2 - HeSai-W (HK02525) reported a net income of RMB 795 million for Q3, a year-on-year increase of 47.5%, and a net profit of RMB 256 million, turning from loss to profit. The full-year net profit guidance has been raised to between RMB 350 million and RMB 450 million, with Q4 revenue expected to be between RMB 1 billion and RMB 1.2 billion, a year-on-year growth of approximately 39% to 67% [2] - China General Nuclear Power New Energy (HK01811) announced a cumulative power generation of 15,753.4 GWh for the first ten months, a year-on-year decrease of 3.5% [6] - Dongyao Pharmaceutical-B (HK01875) reported a revenue of RMB 622 million for the nine months ending September 30, 2025, with a net loss attributable to equity holders of RMB 3.371 million [6] Group 3 - The innovative drug sector saw a collective rise in early trading, with companies like BeiGene up over 4%, Kailaiying up over 1.8%, and others like Zhaoyan New Drug, WuXi AppTec, and WuXi Biologics rising over 1% [6] - In the tech sector, Xiaomi rose over 2%, while Tencent and NetEase increased by over 1%. However, Alibaba and Baidu fell by over 2% [8]

Core Insights - Dongyao Pharmaceutical-B (01875) reported a revenue of RMB 622 million for the nine-month period ending September 30, 2025, indicating the company's financial performance during this timeframe [1] - The company recorded a net loss attributable to equity holders of RMB 3.371 million during the same period, highlighting ongoing financial challenges [1] Financial Performance - Revenue for the nine-month period was RMB 622 million, reflecting the company's operational scale [1] - The net loss for the period was RMB 3.371 million, which indicates a negative financial outcome for equity holders [1]

格隆汇11月11日丨东曜药业-B(01875.HK)公布截至2025年9月30日止九个月之若干未经审核财务资料。 前三季度营收约为人民币6.22亿元，同比下降约23.15%。净亏损337万元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 – 1 – 重要提示 誠 如 上 文 所 述，本 公 告 所 載 本 集 團 截 至2025年9月30日止九個月之業績乃未經 審 核。本 集 團 之 過 往 營 運 業 績 存 在 波 動，且 於 未 來 從 一 個 期 間 至 另 一 期 間 可 能 持 續 波 動。因 此，本 集 團 於 任 何 期 間 之 營 運 業 績 不 應 被 視 為 任 何 未 來 期 間 預 期 業 績 之 指 標。本 公 司 股 東 及 潛 在 投 資 者 在 買 賣 本 公 司 證 券 時 務 請 審 慎 行 事。 截 至2025年9月30日 止 九 個 月 期 間，本 集 團 之 營 業 收 入 為 人 民 幣621,670千 元，較 去年同期下降23%，主 要 係 由 於 自 研 產 品 的 市 場 競 爭 愈 加 激 烈。 BioDlink Interna ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 東曜藥業股份有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 不適用 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01875 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | | 已發行股份總數 | | | 上月底結存 | | | 772,787,887 | | | 0 | | 772,787,887 | | 增加 / 減少 (-) | | | | 0 | | 0 | | | | 本月底結存 | | | 772,787,887 | | | 0 | ...

Core Insights - The successful shipment of the first batch of Bevacizumab biosimilar to Colombia marks a significant milestone for the company in deepening its presence in the Latin American market [1] Group 1: Overseas Commercialization Strategy - The company has been actively advancing the overseas registration of its collaborative products, receiving industry acclaim for its "multi-country registration" commercial efficiency [2] - The innovative "global selection + global coverage" outbound platform model has led to partnerships with several well-known pharmaceutical companies, securing over twenty key products for overseas commercialization across diverse therapeutic areas [2] - Colombia, as the fourth largest pharmaceutical market in Latin America, has seen a notable increase in the export of Chinese pharmaceutical products, with a 10.4% year-on-year growth in the first quarter of 2025 [2] Group 2: Regulatory and Market Entry - The Colombian pharmaceutical market is a key focus for the company, with the local regulatory body INVIMA's standards closely aligned with international authorities like the FDA and EMA, indicating a high level of market entry rigor [2] - The INVIMA certification is expected to facilitate the introduction of Bevacizumab in other Latin American markets, enhancing the company's overall market penetration strategy [2] Group 3: Collaborative Efforts and Future Plans - The successful commercialization of Bevacizumab overseas is attributed to the deep collaboration between the company and its partner, which ensures stringent production compliance and high product quality [3] - The company plans to continue advancing the registration of Bevacizumab in Latin America and other key markets, while also enhancing its local operational capabilities for other products [3] - The ongoing efforts aim to expand the company's international footprint and provide hope for more patients through access to essential medications [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 BioDlink International Company Limited 東曜藥業股份有限公司 （於 香 港 註 冊 成 立 的 有 限 公 司） （股 份 代 號：1875） 有 關 董 事、首 席 執 行 官、授 權 代 表 及 董 事 委 員 會 組 成 的 變動的補充公告 付山先生 執行董事 香 港，2025年10月16日 於 本 公 告 日 期，本 公 司 執 行 董 事 為 付 山 先 生；本 公 司 非 執 行 董 事 為 劉 衛 東 博 士；及 本 公 司 獨 立 非 執 行 董 事 為 孫 暉 女 士、張 勍 先 生 及 谷 學 林 博 士。 (i) 由 於 個 人 原 因，劉 博 士 辭 任 本 公 司 執 行 董 事、首 席 執 行 官、首 席 科 學 官 及 戰略及ESG委 員 會 成 員；及 (ii) 由 於 個 人 ...

Core Viewpoint - Dongyao Pharmaceutical-B (01875) announced significant changes in its executive leadership, effective October 11, 2025, with Mr. Fu Shan transitioning from a non-executive director to an executive director, while Dr. Liu Jun and Ms. Huang Chunying will resign from their respective positions due to personal reasons [1]. Group 1: Leadership Changes - Mr. Fu Shan will lead and oversee the management and development of the group after his transition to executive director [1]. - Dr. Liu Jun will resign from his roles as executive director, CEO, chief scientific officer, and member of the strategic and ESG committee due to personal reasons [1]. - Ms. Huang Chunying will resign from her positions as non-executive director, vice-chairman, and member of the strategic and ESG committee, also due to personal reasons [1]. Group 2: Compliance and Representation - Following Dr. Liu's departure, Mr. Fu Shan has been appointed as the company's authorized representative in accordance with Listing Rule 3.05, effective from October 11, 2025 [1].